SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility following a press address where the administration indicated a prolonged military commitment in the Middle East, sparking investor concerns over potential energy inflation and long-term geopolitical instability. Market participants are actively debating whether this signals a genuine shift in economic conditions or if it is another instance of price manipulation, with many choosing to avoid holding positions over the upcoming long holiday weekend.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is facing intense volatility as market participants react to ongoing uncertainty surrounding the administration's military rhetoric in the Middle East and shifting geopolitical alliances. Community discourse is heavily polarized, with active debates ranging from concerns over interest rate policies and inflationary pressures to fierce criticism of presidential communications and the broader impact of current geopolitical tensions on the markets.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Market participants are intensely focused on the upcoming presidential address regarding the Iran conflict, with community debate split between expecting a major de-escalation announcement and concerns that the speech will merely justify a continued military presence. Traders are closely monitoring the potential for a 'sell the news' reaction following a sharp rally, while active discussions highlight ongoing uncertainty regarding oil supply and the geopolitical stability of the Strait of Hormuz.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is surging as investors react to a strategic $2 billion partnership with Marvell, which is boosting confidence in the AI infrastructure ecosystem. While the stock is catching a massive wave of bullish sentiment, the community remains divided, with many traders closely watching geopolitical developments in the Middle East and upcoming economic reports for signs of further volatility.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending as investors react to conflicting signals surrounding the Iran-U.S. conflict, with the community actively debating whether recent diplomatic overtures are genuine moves toward de-escalation or tactical market manipulation ahead of an upcoming national address. Despite volatility, traders remain focused on the strategic importance of the Strait of Hormuz and the potential for a sustained geopolitical energy risk premium.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors weigh anticipation for upcoming Q1 delivery results against broader market volatility and speculation surrounding a potential SpaceX IPO. Community discourse remains deeply divided between bullish sentiment regarding the company's long-term autonomy and robotics roadmap, and intense bearish concerns over slowing EV demand and high-profile geopolitical tensions.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as traders weigh conflicting reports regarding potential de-escalation in the Middle East and upcoming policy addresses from U.S. leadership. The community remains deeply divided, with some investors accumulating on dips due to long-term scarcity narratives while others express caution over macroeconomic headwinds and bearish chart patterns.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense investor scrutiny and volatility as community members weigh the impact of heavy AI infrastructure spending against broader geopolitical tensions and recent software-focused concerns. The stock remains a focal point for institutional put activity, with ongoing debates among traders regarding whether current price levels represent a deep-value opportunity or a precursor to further downside.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid intense debate over the company's reliance on debt-funded Bitcoin acquisitions, with traders sharply divided between bullish hopes for a massive price recovery and bearish concerns regarding dilution and potential liquidity risks. The stock is seeing high volatility and heavy options activity as market participants closely monitor the underlying performance of Bitcoin and broader macro uncertainties.

Applied Digital Corporation

Applied Digital is drawing significant attention as investors weigh a major credit upgrade for its data centers against lingering macroeconomic anxieties and geopolitical concerns. While community sentiment is polarized, traders are actively monitoring upcoming earnings and the potential for new hyperscaler lease announcements, keeping options activity high as the market assesses whether the recent volatility represents a buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company outlined progress on its anticoagulation pipeline, including its HIT program VLX-1005, at a Lytham Partners investor summit.</li><li>Cadrenal said VLX-1005 has completed a Phase 2 trial, with data under review and FDA discussions planned.</li><li>Shares fell 4% on Friday before ticking higher after the close.</li></ul>Cadrenal Therapeutics drew renewed retail investor interest on Tuesday after&nbsp;the biotech company&nbsp;outlined progress across its anticoagulation pipeline, VLX-1005,&nbsp; which it&nbsp;acquired from Veralox Therapeutics in December.At a&nbsp;fireside chat at the Lytham Partners Healthcare Investor Summit,&nbsp;Cadrenal CEO Quang Pham and acting Chief Scientific Officer Matt Boxer described how the asset fits into the company’s broader strategy to address gaps left by long-standing anticoagulants such as Warfarin and Heparin, as well as newer direct oral anticoagulants (DOACs).The stock fell 4% to close at $7.87 on Friday, before edging up 0.8% in after-hours trading.<h2 class="st-heading-2">Targeting A High-Risk Complication Of Heparin Use</h2>VLX-1005 is being developed for heparin-induced thrombocytopenia, or HIT, a condition caused by an immune reaction to heparin. Boxer said patients exposed to heparin can develop antibodies that form complexes with platelet factor 4.This process leads to platelet consumption while simultaneously triggering clot formation, he said. As a result, patients can develop thrombosis and ischemia, with cases sometimes progressing to amputations, organ failure, and death, even though they were initially given heparin for anticoagulation.Boxer said existing treatments mainly work by inhibiting the clotting cascade, a strategy that can increase bleeding risk in patients with already low platelet counts. He added that about 50,000 confirmed new HIT cases occur each year in the U.S., driven in part by the continued use of heparin in cardiovascular surgery, with cases also seen globally.<h2 class="st-heading-2">Phase 2 Data And Next Steps</h2>VLX-1005 was designed to act earlier in the disease process by blocking 12-lipoxygenase (12-LOX), an enzyme that plays a role in triggering immune-driven platelet activation.&nbsp;The program has completed a Phase 2 clinical trial, with the database locked and data currently under analysis. Pham said the company has been engaging with primary investigators through introductions made by the Veralox team and expects the data to be published in the near term.VLX-1005 has received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA). Pham said work on chemistry, manufacturing and controls is underway, with discussions with the FDA expected later this quarter.<h2 class="st-heading-2">Other Programs In Development</h2>Alongside VLX-1005, Cadrenal is advancing Tecarfarin, a vitamin K antagonist designed to be more kidney-friendly, for patients with end-stage kidney disease and atrial fibrillation, as well as those with implanted mechanical heart valves and left ventricular assist devices. Tecarfarin holds orphan drug designations for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), as well as for those with left ventricular assist devices (LVADs).Pham also referenced Fruinexian, a short-acting Factor XI candidate acquired in late 2025 for use in cardiovascular surgery, noting broader industry interest in Factor XI inhibitors as the company awaits the first approvals in the class.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Cadrenal was ‘neutral’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cvkd_ss_png_379707bd48.webp" alt="cvkd ss.png" width="969" height="140"><figcaption>CVKD sentiment and message volume as of January 19 | Source: Stocktwits</figcaption></figure>One user said, “<a href="https://stocktwits.com/symbol/CVKD">$CVKD</a> is showing early strength.”<stembedurl>https://stocktwits.com/JoannMotta/message/642239634</stembedurl>&nbsp;Another user described the stock’s current levels as a zone to keep&nbsp;an eye on.<stembedurl>https://stocktwits.com/LydiaBoyce/message/642238255</stembedurl><a href="https://stocktwits.com/symbol/CVKD">Cadrenal’s stock</a> has declined 57% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Cadrenal Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?

The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.

Equity

Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...

Why the underdog mindset could be your business superpower

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...

Cadrenal Therapeutics, Inc.  

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

CVKD
Cadrenal Therapeutics, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CVKD News

CVKDCadrenal Therapeutics, Inc.